That rise came despite the approval of Merck & Co's 15-valent Vaxneuvance in July 2021, which has posed the first major challenge to the Prevnar family. With ASP3772, GSK could offer a shot with ...
The franchise brought in $6.4 billion in worldwide sales last year, although MSD (known as Merck & Co in the US and Canada) has started to claim market share with Vaxneuvance, which covers 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback